Treatment outcomes of multidrug-resistant tuberculosis patients in Gauteng, South Africa
- PMID: 24363208
- DOI: 10.1007/s15010-013-0572-2
Treatment outcomes of multidrug-resistant tuberculosis patients in Gauteng, South Africa
Abstract
Purpose: Multidrug-resistant tuberculosis (MDR-TB) is associated with lengthy treatment, expensive and potentially toxic regimens, and high rates of treatment failure and death. This study describes the outcomes of 351 MDR-TB patients who started treatment between 2004 and 2007 at the provincial MDR-TB referral hospital in Johannesburg, South Africa, and investigates risk factors associated with death.
Methods: The study involved the assessment of factors associated with treatment outcomes using a retrospective review of patient records, drug-susceptibility data and spoligotyping of isolates.
Results: Treatment success (completion/cure) was recorded in 158 (48.8 %) patients, while 65 (20 %) died, 93 (28.7 %) defaulted, 8 (2.5 %) failed treatment, 11(3.1 %) were transferred out to other health facilities and 16 (4.6 %) had no recorded final outcome. The proportion of successful treatment increased significantly over time. Univariable and multivariable analysis (P = 0.05) identified the year of MDR-TB diagnosis and spoligotype-defined families as factors associated with treatment outcome. No associations were found between treatment outcome and human immunodeficiency virus (HIV) status, previous TB and additional MDR resistance to streptomycin or ethambutol. Molecular typing of the strains revealed a diverse group of spoligotypes, with Beijing, LAM4 and H3 making up the largest groups.
Conclusions: This is the first published study to investigate treatment outcomes at this facility and to find a link between genotype and treatment outcome, suggesting that genotype determination could potentially serve as a prognostic factor.
Similar articles
-
Molecular characterization and second-line antituberculosis drug resistance patterns of multidrug-resistant Mycobacterium tuberculosis isolates from the northern region of South Africa.J Clin Microbiol. 2012 Sep;50(9):2857-62. doi: 10.1128/JCM.00358-12. Epub 2012 May 30. J Clin Microbiol. 2012. PMID: 22649019 Free PMC article.
-
Epidemic spread of multidrug-resistant tuberculosis in Johannesburg, South Africa.J Clin Microbiol. 2013 Jun;51(6):1818-25. doi: 10.1128/JCM.00200-13. Epub 2013 Apr 3. J Clin Microbiol. 2013. PMID: 23554196 Free PMC article.
-
Molecular characterization of multidrug-resistant Mycobacterium tuberculosis (MDR-TB) isolates identifies local transmission of infection in Kuwait, a country with a low incidence of TB and MDR-TB.Eur J Med Res. 2019 Dec 5;24(1):38. doi: 10.1186/s40001-019-0397-2. Eur J Med Res. 2019. PMID: 31806020 Free PMC article.
-
Predictors of cure among HIV co-infected multidrug-resistant TB patients at Sizwe Tropical Disease Hospital Johannesburg, South Africa.Trans R Soc Trop Med Hyg. 2015 May;109(5):340-8. doi: 10.1093/trstmh/trv025. Epub 2015 Mar 18. Trans R Soc Trop Med Hyg. 2015. PMID: 25787727 Review.
-
Emergence and treatment of multidrug resistant (MDR) and extensively drug-resistant (XDR) tuberculosis in South Africa.Infect Genet Evol. 2012 Jun;12(4):686-94. doi: 10.1016/j.meegid.2011.07.019. Epub 2011 Aug 4. Infect Genet Evol. 2012. PMID: 21839855 Review.
Cited by
-
Comorbidities and treatment outcomes in multidrug resistant tuberculosis: a systematic review and meta-analysis.Sci Rep. 2018 Mar 21;8(1):4980. doi: 10.1038/s41598-018-23344-z. Sci Rep. 2018. PMID: 29563561 Free PMC article.
-
A systematic review of risk factors for mortality among tuberculosis patients in South Africa.Syst Rev. 2023 Feb 23;12(1):23. doi: 10.1186/s13643-023-02175-8. Syst Rev. 2023. PMID: 36814335 Free PMC article.
-
Early Outcomes Of Decentralized Care for Rifampicin-Resistant Tuberculosis in Johannesburg, South Africa: An Observational Cohort Study.PLoS One. 2016 Nov 3;11(11):e0164974. doi: 10.1371/journal.pone.0164974. eCollection 2016. PLoS One. 2016. PMID: 27812140 Free PMC article.
-
Treatment outcomes of patients with multidrug and extensively drug-resistant tuberculosis in Zhejiang, China.Eur J Med Res. 2021 Apr 3;26(1):31. doi: 10.1186/s40001-021-00502-0. Eur J Med Res. 2021. PMID: 33812390 Free PMC article.
-
Rifampicin resistance and mortality in patients hospitalised with HIV-associated tuberculosis.South Afr J HIV Med. 2022 Sep 27;23(1):1396. doi: 10.4102/sajhivmed.v23i1.1396. eCollection 2022. South Afr J HIV Med. 2022. PMID: 36299556 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources